RMC-5127, a novel tri-complex inhibitor with efficacy in KRAS G12V-mutant tumor models

Oct. 23, 2023

Researchers from Revolution Medicines Inc. presented the discovery and preclinical characterization of RMC-5127, a novel noncovalent, tri-complex inhibitor of GTPase KRAS (G12V mutant), or KRAS G12V(ON).

BioWorld Science Conferences AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Cancer

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 2, 2025.

Unnatural Products joins Argenx in a $1.5B macrocyclic deal

BioWorld

Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...

Illustration of the β2-adrenergic receptor

Exercise-mimicking compound offers alternative to GLP-1 therapies

BioWorld

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...

CMS eyes competitive bidding for CGMs, insulin pumps

BioWorld MedTech

The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...